RA Capital Management »

4d Molecular Therapeutics In shares owned by RA Capital Management

Quarter-by-quarter ownership of 4d Molecular Therapeutics In (FDMT) shares owned by RA Capital Management from 13F filings

Historical chart of RA Capital Management investment in 4d Molecular Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including 4d Molecular Therapeutics In held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 4d Molecular Therapeutics In by RA Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $84M 4.2M 20.26
2023-09-30 $53M 4.2M 12.73
2023-06-30 $56M 3.1M 18.07

More positions owned by RA Capital Management

Ascendis Pharma A/s - SH (ASND)
Immunogen SH
Vaxcyte SH (PCVX)
Legend Biotech Corp- SH (LEGN)
Rhythm Pharmaceuticals SH (RYTM)
Aerovate Therapeutics SH (AVTE)
Inhibrx SH (INBX)
Cymabay Therapeutics SH
Biogen SH (BIIB)
Rxsight SH (RXST)
89bio SH (ETNB)
Verona Pharma Plc - SH (VRNA)
Day One Biopharmaceuticals I SH (DAWN)
An2 Therapeutics SH (ANTX)
Tyra Biosciences SH (TYRA)

View all positions for RA Capital Management

Top funds holding 4d Molecular Therapeutics In

Viking Global Investors
RA Capital Management
BVF
VR Adviser
Henderson Group
Vanguard Group
Arrowpoint Asset Management
Casdin Capital
Goldman Sachs Group
Dimensional Fund Advisors
Deutsche Bank Aktiengesellschaft
Eagle Health Investments
Assenagon Asset Management
Jpmorgan Chase & Co
Point72 Asset Management

View all funds holding 4d Molecular Therapeutics In